Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry - Final Guidance
FDA-2020-D-1079-0064Other
Comments
7
Last activity Jun 22, 2026
Deadline
--
Net supportiSupport minus oppose · campaigns included
0%
0% excluding campaigns
Document
Details
The document's own metadata, straight from the source system.
- Title
- Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry - Final Guidance
- Posted
- Jan 24, 2023
- Comment period
- Jan 24, 2023 – ?
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Include campaigns
Stance breakdown
0%
Net support
Support2Oppose2Other3
Aggregates include form-letter campaigns. Excluding them, net support is 0% across organic comments.
Who commented
Breakdown by commenter type.
Individual
6
Advocacy
1
Comments over time
Weekly arrivals, stacked by stance.
Posted Jan 24, 2023
Jan 23Oct 7Oct 27Mar 16May 25Jun 22
Support2Oppose2Other3
Support × commenter type
How each type splits across stance.
Support
Oppose
Other
Individual
33%
33%
33%
Advocacy
0%
0%
100%
Issues raised
The docket's canonical issues. Select one to browse its comments.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.